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Abstract
Background: Elucidation of epigenetic alterations in bladder cancer will lead to further understanding of the
biology of the disease and hopefully improved therapies. Our aim was to perform an integrative epigenetic analysis
of invasive urothelial carcinoma of the bladder to identify the epigenetic abnormalities involved in the
development and progression of this cancer.
Methods: Pre-processed methylation data and RNA-seq data were downloaded from The Cancer Genome Atlas
(TCGA) and processed using the R package TCGA-Assembler. An R package MethylMix was used to perform an analysis
incorporating both methylation and gene expression data on all samples, as well as a subset analysis comparing
patients surviving less than 2 years and patients surviving more than 2 years. Genes associated with poor prognosis
were individually queried. Pathway analysis was performed on statistically significant genes identified by MethylMix
criteria using ConsensusPathDB. Validation was performed using flow cytometry on bladder cancer cell lines.
Results: A total of 408 patients met all inclusion criteria. There were a total of 240 genes differentially methylated by
MethylMix criteria. Review of individual genes specific to poor-prognosis patients revealed the majority to be candidate
tumor suppressors in other cancer types. Pathway analysis showed increase in methylation of genes involved in
antioxidant pathways including glutathione and NRF2. Genes involved in estrogen metabolism were also
hypermethylated while genes involved in the EGFR pathway were found to be hypomethylated. EGFR expression
was confirmed to be elevated in six bladder cancer cell lines.
Conclusions: In patients with invasive urothelial carcinoma, we found differential methylation in patients with better
and worse prognosis after cystectomy. Differentially methylated genes are involved in many relevant oncologic
pathways, including EGFR and antioxidant pathways, that may be a target for therapy or chemoprevention.
Keywords: Epigenetics, Urothelial carcinoma, Integrative analyses
Background
Urothelial carcinoma of the bladder is the eighth most
common form of cancer in the USA and the fourth most
common type of cancer in men [1]. Although the major-
ity of urothelial carcinoma of the bladder is diagnosed at
a non-invasive stage, 30–40% of cases will progress to
invade the deeper muscle layer of the bladder [2], at
which point the long-term disease-specific survival is
50–70% [3, 4].
Multiple studies have shown that DNA methylation,
the process by which a methyl group is added to a cyto-
sine residue of a cytosine-phosphate-guanine (CpG)
dinucleotide, plays an important role in the initiation
and progression of bladder cancer [5–7]. DNA methyla-
tion represents a promising target for therapy since
DNA methylation is a reversible process that does not
alter the content of DNA [8].
High-throughput methods have been employed in
bladder cancer to evaluate the epigenetic alterations in-
volved in the development and progression of this dis-
ease [5, 9]. However, many methylation events found to
be statistically significant using high-throughput screen-
ing methods are not correlated with gene expression
changes [10]. There is a need for high-throughput ap-
proaches that integrate data across multiple platforms to
determine the epigenetic events that are most likely to
be involved in bladder cancer [11].
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The Cancer Genome Atlas (TCGA) project demon-
strated impressive diversity in both genetic and epigen-
etic alterations within patients who have muscle-invasive
urothelial carcinoma of the bladder [12]. The multiple
platforms utilized within TCGA make it possible to per-
form analyses integrating data from multiple sources to
identify specific abnormalities most likely to contribute
to oncogenic processes. In this study, we utilized an in-
tegrative approach to evaluate the epigenetic processes
that may be most important in development and
progression of invasive urothelial carcinoma.
Methods
Data acquisition and preprocessing
All data were obtained from bladder cystectomy speci-
mens from The Cancer Genome Atlas Project [13]. Spe-
cimen acquisition and processing is described in detail
in the original TCGA publication, but briefly: specimens
were placed in optimum cutting temperature media and
frozen. Normal tissues (N = 21) were taken from the
cystectomy specimens 2 cm away from tumor. All
tumors included in TCGA had less than 50% of variant
(non-urothelial) histology.
Methylation was evaluated on the Illumina Infinium
HumanMethylation450 platform, which assesses 482,421
CpG sites throughout the genome [14]. Level 3 methyla-
tion data were downloaded from the TCGA data portal
using the TCGA-Assembler DownloadMethylationData
function [15]. Level 3 data consist of pre-processed data
via TCGA pipelines in the form of beta values, which are a
ratio between methylated probe intensities and total probe
intensities (https://cancergenome.nih.gov/abouttcga/about
data/datalevelstypes). Probe-level data was condensed to a
summary beta value for each gene using the Methyla-
tion450_single_value function in TCGA-Assembler, which
calculates the average methylation value for all CpG sites
associated with a gene. Level 3 RNA-seq data were also
obtained from the TCGA data portal using the TCGA-
Assembler function DownloadRNASeqData. The functions
DGEList and calcNormFactors functions from the edgeR
package were used to normalize the data [16]. The voom
function from the limma package was then used to trans-
form the RNA-seq data for linear modeling [17]. Both
tumor tissue and normal tissue were processed in an iden-
tical manner.
Clinical data
Clinical data for TCGA patients were obtained via the
TCGA data portal. To augment and validate the patho-
logic data (of which not all variables were complete),
pathology reports were downloaded from cbioportal.com
for all patients in the TCGA provisional dataset and
pathologic data were individually reviewed. All patients
included in TCGA had muscle-invasive disease (pT2-
T4). Of the 412 patients in the dataset, 408 had
complete clinical, gene expression, and methylation data.
A total of 101 patients met inclusion criteria for survival
of at least 2 years after cystectomy. A total of 142 pa-
tients died within 2 years after cystectomy. This left a
total of 165 patients with inadequate follow-up to be in-
cluded in the survival analysis. Clinical data were parti-
tioned into three separate groups for analysis. First, we
performed analysis of the entire dataset (N = 408). Next,
we performed analysis of patients who survived more
than 2 years after cystectomy versus patients who died
within 2 years of cystectomy.
Integrative analysis
The R package MethylMix was used to perform an ana-
lysis integrating methylation data and gene expression
(RNA-seq) data [18]. MethylMix is a program designed
to identify methylation events that are correlated with
gene expression [19]. There are three parts to the
MethylMix analysis: first, methylation data are correlated
with gene expression data to identify methylation events
that results in gene expression changes—only genes
passing the correlation filter are selected for further ana-
lysis; second, a beta mixture model is used to define a
methylation state across a large number of patients, pre-
cluding the need for arbitrary thresholds; and third, a
Wilcoxon rank sum test is used to compare DNA
methylation states in tumor samples versus normal sam-
ples [18]. Multiple testing is accounted for using a q
value cutoff of 0.05. The end result is a differential
methylation (DM) value where a positive DM value sig-
nifies hypermethylation and a negative DM value signi-
fies hypomethylation.
Pathway analysis
Pathway analysis was performed with ConsensusPathDB
[20]. ConsensusPathDB utilizes a hypergeometric test to
evaluate for over-represented pathways based on the
imputed gene list. The over-representation analysis
function was utilized imputing the HUGO Gene
Nomenclature Committee (HGNC) unique identifiers for
each gene list. The following pathway databases were se-
lected for our analysis: Inoh, Pid, Biocarta, Netpath,
Humancyc, Kegg, Wikipathways, Smpdb, Pharmgkb,
Ehmn, and Signalink. We used the default settings: mini-
mum overlap and p value cutoff of 0.01.
Pathway analysis was performed using the gene lists
found to be statistically significant by MethylMix. Lists
of hypermethylated genes were analyzed separately from
lists of hypomethylated genes for the followed groups:
all patients, patients who survived at least 2 years after
cystectomy, and patients who died within 2 years of
cystectomy.
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Experimental validation in bladder cancer cell lines
The following bladder cancer cell lines were obtained
from ATCC (Manassas, VA, USA): ScaBER (HTB-3),
HT1376 (CRL-1472), SW780 (CRL-2169). Dr. David
McConkey kindly gifted three additional cell lines
UMUC-5, UMUC-1, and 253J (University of Texas, MD
Anderson Cancer Center). All the cell lines were grown
in the same media, which was minimum essential media
(MEM) (Life Technologies) supplemented with 10% fetal
bovine serum, 1% penicillin/streptomycin, and 1% Gluta-
MAX (Life Technologies). The presence of surface EGFR
on the cell lines listed above was determined by flow
cytometry. For each cell line, a single cell suspension
was obtained after trypsinzation (~ 1 × 106 cells/tube),
which was incubated in the presence of phycoery-
thrin(PE)-tagged rat monoclonal antibody to human
EGFR (Abcam) or PE-tagged rat IgG2a kappa monoclo-
nal antibody (isotype control; Abcam). The cells were
allowed to incubate for 30 min at 4 °C in the antibody
solution. We washed the cells to remove all unbound
antibody using phosphate-buffered solution. Fluores-
cence was measured on a FACS Calibur flow cytometer
(BD BioSciences).
Statistical analysis
Continuous variables were evaluated using the
Student t test. Categorical variables were evaluated
using chi-squared. p value less than 0.05 was consid-
ered statistically significant. All analyses were per-
formed using R v 3.3.2. Flow cytometry data were
analyzed using FlowJo (Treestar Inc.).
Results
Clinical data
Clinical characteristics are summarized in Table 1 and
represent the three groups used for analysis. There was a
statistically significant difference between the groups
with respect to age, with patients surviving more than
2 years being younger. However, there were no signifi-
cant differences between the groups for T stage [21].
MethylMix analysis: hypermethylated versus
hypomethylated genes by prognostic category
A total of 240 genes were differentially methylated when
comparing tumor to normal by MethylMix criteria for
all 408 patients. Example of differential methylation of
tumor samples compared with normal samples is dem-
onstrated in Fig. 1. Of these genes, 70 genes (29%) were
hypermethylated and the remainder of the genes were
hypomethylated. When MethylMix analysis was per-
formed on the subset of patients surviving at least 2 years
after cystectomy, a total of 266 genes reached statistical
significance of which 69 (26%) were hypermethylated.
There were a total of 220 significant genes when Methyl-
Mix was performed on the cohort of patients who died
within 2 years of cystectomy, of which 70 (32%) were
hypermethylated (Fig. 2). There was a slightly higher
proportion of genes hypermethylated in patients in the
worse prognosis group (survive < 2 years) when
compared with the group with better prognosis (survive
> 2 years), but this difference was not statistically signifi-
cant (p = 0.18).
When the differentially methylated genes in the group
that survived more than 2 years were compared with dif-
ferentially methylated genes in the group that survived
less than 2 years, nearly half of the genes (49%) over-
lapped between the better and worse prognosis cohorts.
There were a total of 24 genes (26%) that were uniquely
hypermethylated in the worse prognosis group and 23
genes (25%) uniquely hypermethylated in the better
prognosis group. When the overlap of hypomethylated
genes was evaluated, there was 52% overlap. The propor-
tion of genes unique to the poor-prognosis group in the
hypomethylated group was less than the hypermethy-
lated group (13 versus 25%, respectively, p = 0.02). Iden-
tities of all genes significant by MethylMix are included
in Additional file 1: Table S1.
Table 1 Clinical data
Characteristic Total Survive > 2 years
after surgery
Death < 2 years
of surgery
Inadequate
follow-up
p value
Cohort size 408 101 142 165
Mean age, years (SD) 68.0 (10.6) 66.2 (10.7) 70.6 (9.5) 69.3 (10.7) < 0.01
Gender
Women (%)
Men (%)
106 (26%)
302 (74%)
24 (24%)
77 (76%)
41 (29%)
101 (71%)
51 (31%)
114 (69%)
0.45
T stage
pT2
pT3
PT4
NA
120 (29%)
196 (48%)
59 (14%)
33 (8%)
37 (37%)
44 (44%)
11 (11%)
9 (9%)
24 (17%)
76 (54%)
29 (20%)
13 (9%)
43 (26%)
82 (50%)
25 (15%)
15 (9%)
0.06
p value determined by ANOVA for continuous variables and chi-square for categorical variables
Sanford et al. Clinical Epigenetics  (2018) 10:19 Page 3 of 11
Evaluation of genes hypermethylated in patients
surviving < 2 years
We sought to evaluate the genes hypermethylated in the
patients unique to patients surviving less than 2 years to
evaluate any potential biologic effect (Additional files 2,
3, and 4). We began by performing a literature search of
PubMed for each gene using the terms “[GENE
NAME]”, “methylation”, “cancer.” Of the 24 genes
unique to patients who died within 2 years of surgery,
19 had been described as being candidate tumor sup-
pressor genes or hypermethylated in various cancer
types, including urothelial carcinoma (Table 2). Nine of
these genes had been shown to be associated with an
aggressive phenotype in prior studies, some in multiple
cancer types. Furthermore, some prior studies performed
experimental validation of pathway alterations for many
of these genes, including the estrogen signaling pathway.
Cumulative effects
While MethylMix describes each gene individually, we
also wanted to evaluate the cumulated dose of hyperme-
thylation across genes in any given patient. Thus, we
assessed the effect of cumulative methylation changes
for the 24 genes unique to patients with poor prognosis.
Across the entire matrix of methylation values, the aver-
age methylation value (beta value) for normal samples
Fig. 1 Summary of top hypermethylated and top hypomethylated genes. The red line demarcates the distribution of methylation in tumor
samples and normal samples. The histogram (below red line) demonstrates the distribution of methylation in tumor samples (denoted as
beta values where higher beta values represent greater methylation). The horizontal black bar above the red line represents the distribution
of methylation values in the normal samples
Fig. 2 Of the 220 statistically significant genes for patients who died within 2 years, 32% were hypermethylated. Of the 266 statistically significant
genes for patients who survived more than 2 years after cystectomy, 26% were hypermethylated and the remainder of the genes were hypomethylated.
For both hypermethylated and hypomethylated genes, the majority of genes were shared by the better and worse prognosis groups. However, there
were some genes with unique methylation status between the two groups, and there were more genes uniquely hypermethylated in the group that
did not survive 2 years compared with the group that survived at least 2 years (p = 0.02). Identities of all genes significant by MethylMix are included in
Additional file 1: Table S1
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for these genes was 0.23, whereas the average methylation
value for tumor samples was 0.39 (p < 0.01). Figure 3 is a
heatmap of the methylation values of all patients with sur-
vival of less than 2 years with poor prognosis genes se-
lected. This heatmap demonstrates patients who survive
less than 2 years may have hypermethylation of multiple
genes associated with hypermethylation in various cancer
types and/or poor prognosis.
Pathway analysis
Figure 4 is a graphical representation of pathways
enriched for genes significant by MethylMix criteria in
the analysis that included all 408 patients. There were
unique pathways represented by analysis of hypermethy-
lated and hypomethylated genes. For hypermethylated
genes, pathways involved in management of free radicals
were found to be significant—both the glutathione and
Table 2 Hypermethylated genes by MethylMix criteria unique to patients who survived less than 2 years after cystectomy
(references listed in Additional file 3: Table S3)
Gene symbol Gene name Chromosome Associated with
aggressive behavior
in cancer
Tumor suppressor/
hypermethylated
in cancer
Altered pathways Cancer types
CXCL6 C-X-C motif
chemokine ligand 6
4q13.3 [44] Ovarian cancer [44]
ZFP42 ZFP42 zinc finger protein 4q35.2 Sox2, NOTCH/
STAT3 [45]
Human embryonic
stem cell marker [45]
PITX1 Paired-like homeodomain 1 5q31.1 [46, 47] Kidney cancer [46]
Hepatocellular cancer
[47]
RSPH9 Radial spoke head 9
homolog
6p21.1 [48] [49] Bladder cancer [50]
Hepatocellular cancer
HIST1H3E Histone cluster 1 H3
family member e
6p22.2 [51] Glioma [51]
SP8 Sp8 transcription factor 7p21.2 Wnt/B-Catenin [52]
TAC1 Tachykinin precursor 1 7q21-q22 [46, 53, 54] [55] Head/neck cancer [53]
Colorectal cancer [54, 55]
Esophageal cancer [46]
PON3 Paraoxonase 3 7q21.3 [56, 57] Bladder cancer [56]
Prostate cancer [57]
ABF1 Musculin
(activated B cell factor 1)
8q13.3 [58] Lymphoma [58]
FOXE1 Forkhead box E1 9q22 [59] [60] Estrogen
signaling [61]
Colorectal carcinoma [59]
Cutanous squamous
cell cancer [60]
Thyroid cancer [62]
CCDC67 Deuterosome assembly
protein 1
11q21 [63] [64] Thyroid carcinoma [63]
Gastric carcinoma [64]
ALX1 ALX homeobox 1 12q21.31 [65] [66] Snail [67] Breast cancer [66]
Non-small cell
lung cancer [65]
Ovarian cancer [67]
SLC6A15 Solute carrier family 6
member 15
12q21.31 [68, 69] Colorectal carcinoma
[68, 69]
EID3 EP300 interacting inhibitor
of differentiation 3
12q23.3 [70] Colorectal cancer [70]
NKX2-8 NK2 homeobox 8 14q13.3 [71] [72, 73] NF-KB [72], MEK/ERK
[71]
Bladder cancer [71]
Cervical cancer [73]
Esopheageal cancer [72]
DIO3 Deiodinase,
iodothyronine type III
14q32 [74, 75] Lung cancer [74]
Hematologic
malignancies [75]
FOXC2 Forkhead box C2 16q24.1 [76] MPK/AKT Breast cancer [76]
HSPB6 Heat shock protein family
B (small) member 6
19q13.13 [77] Melanoma [77]
ZNF382 Zinc finger protein 382 19q13.13 [78] NF-kB [79] Esophageal cancer [78]
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NRF2 pathways are key antioxidant pathways [6]. The
estrogen metabolism pathway was also enriched in
hypermethylated genes. The chemical carcinogenesis
pathway was also hypermethylated, consistent with
the relationship between bladder cancer and environ-
mental exposures such as tobacco smoking and cyclic
amines [22]. The most notable hypomethylated path-
way was the EGFR1 pathway, a well-known oncogene
that has been shown to be over-expressed in multiple
cancer types [23]. Genes in the cyclophosphamide
pathway were found to be hypomethylated—this agent
can have significant effects on the urothelium causing
hemorrhagic cystitis as well as delayed malignancy.
There were also multiple pathways involved in fatty
acid metabolism. Additional file 2: Table S2 lists de-
tailed pathway analysis results by methylation status
and patient group.
Flow cytometry confirms the presence of EGFR
There was a substantial amount of EGFR in all six cell
lines tested, reflecting hypomethylation (Fig. 5). There
was a mean increase of 83-fold over isotype control. The
mean intensity for isotype control was 81.7 (range 12.5–
154) while the EGFR mean intensity was 6816 (range
1544–11,222), t test p value < 0.01 (Fig. 5).
Discussion
Epigenetic changes and modifications are an important
part of carcinogenesis and subsequent tumor progres-
sion [24, 25]. Of the various epigenetic mechanisms,
DNA methylation has been most studied and is classic-
ally associated with gene silencing via hypermethylation
of CpG islands located in promoter regions of tumor
suppressor genes. DNA hypomethylation has also been
implicated in the development of cancer and likely
results in genome rearrangement and chromosomal
instability. Alterations in DNA methylation may be in-
volved in the development of urothelial carcinoma of the
bladder, with abnormalities identified in the normal
urothelium of those who later develop frank cancer [5].
However, the methylation status of specific genes has been
shown to be associated with worse prognosis [9, 10, 26],
indicating that epigenetic changes may also be involved in
tumor progression.
The earliest studies demonstrating the role of methy-
lation in the development of urothelial carcinoma
demonstrated a relationship between adverse clinical
outcomes and the methylation state of promoters of
specific genes known to be involved in the development
of cancer [6, 7, 27]. These gene-specific studies demon-
strated the relationship between increased methylation
of specific gene promoters and grade [27], stage [28],
Fig. 3 Heatmap of methylation values (beta values) for 24 genes uniquely hypermethylated in patients who survived less than 2 years after
cystectomy. The gray bar histogram represents the mean beta value across all genes for each patient
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and progression [7]. In addition to hypermethylation of
specific genes, there was also evidence of an association
between hypermethylation of multiple genes (character-
ized by a methylation index) and increased cancer
aggressiveness [27].
The widespread use of high-throughput arrays created
an opportunity to discover new genes involved in the
epigenetic regulation of carcinoma [9, 29–31]. We
sought to further elucidate the role and importance of
methylation in bladder cancer by applying an integrative
analysis tool to The Cancer Genome Atlas Project [32].
Although the TCGA has revealed the remarkable diver-
sity of genetic alterations in bladder cancer, with only
lung cancer harboring more mutations per megabase, it
is clear that not all identified abnormalities contribute
to the development of urothelial cancer, as many events
deemed abnormal using high-throughput screening may
have no biologic effect [33]. Fan et al. evaluated the rela-
tionship between methylation status in the promotor of
90 genes and RNA expression in six tissue types and
found no correlation between methylation status and
gene expression [34]. In bladder cancer, Lauss et al.
demonstrated only 8% of methylated genes had an effect
on gene expression [10]. When using high-throughput
methodology with 450,000 probes, there is a need to
distinguish the epigenetic alterations that act as
effectors of the malignant phenotype from “passenger”
alterations with no biologic effect. Thus, we used a
model-based tool (MethylMix) to identify those genes
with aberrant methylation and linked these data to
RNA-seq data reflecting gene expression. This tool has
been shown to produce results consistent with other
methods of integrative analysis but also to produce
unique findings [19]. The marriage of these complemen-
tary “omics” may aid in revealing biologically and clinic-
ally relevant information [11].
Our study corroborates findings from prior studies. We
found increases in methylation of specific genes were
associated with more aggressive disease [27, 35, 36], and
we found a slightly greater proportion of genes being
hypermethylated in the group who survived at least 2 years
when compared to the group that died within 2 years of
surgery. Although there was some overlap in statistically
significant genes between patients with better versus worse
survival, there were 24 genes that were unique to the group
with worse survival. While the evaluation of these genes
showed the majority were candidate tumor suppressor
genes in a variety of cancers, this is the first time most of
Fig. 4 Select pathways enriched for genes hypermethylated and hypomethylated by MethylMix criteria in the analysis including all patients in
the TCGA cohort. The full list of pathways is included in Additional file 2: Table S2
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these genes have been associated with bladder cancer. This
provides validation of the methodology and also provides
an opportunity to evaluate the effect of cumulative methy-
lation events. As a proof of principle, we show that many
patients had hypermethylation of multiple poor-prognosis
genes, suggesting that there may be many combinations of
hypermethylation events that can lead to poor prognosis.
Our pathway analysis provided an opportunity to
evaluate the gene lists produced by integrative analysis
of all three patient groups, which is unique to our study.
In examining all patients, one interesting finding from
our pathway analysis was the enrichment of hyper-
methylated genes involved in antioxidant pathways.
Genes involved in both glutathione-mediated detoxifica-
tion as well as the nuclear factor (erythroid-derived)-like
2 (NRF2) pathway were statistically significantly hyper-
methylated, and both are integral in the cellular defense
against oxidative stress. Glutathione is the most plentiful
intracellular antioxidant and is a key component of
redox-dependent regulation [37]. NRF2 is a transcription
factor that serves as a key regulator in the cellular re-
sponse to oxidative stress via induction of genes involved
in the response to oxidative stress and xenobiotics, includ-
ing those that regulate glutathione [38]. Deficiency of
NRF2 has been shown to contribute to the development
of cancer. In mice, knockout of the NRF2 gene increased
susceptibility to formation of invasive bladder tumors in
response to administration of a carcinogen [39].
In addition, there were two other notable findings. First,
our pathway analysis enriched for hypermethylation of
genes involved in the metabolism of estrogen. This is con-
sistent with evidence for the role of estrogens in bladder
cancer and suggests a basis for the observed clinical differ-
ences in the prevalence of bladder cancer between men
and women. Shen et al. demonstrated that higher expres-
sion of estrogen receptor beta was associated with increas-
ing stage and grade [40], and anti-estrogen compounds
have been shown to inhibit the growth of bladder cancer
cell lines [40, 41]. Targeting this pathway with anti-
estrogens may have a therapeutic role in specific patients
[42]. A second interesting observation was enrichment of
hypomethylated genes associated with the epidermal
growth factor receptor (EGFR) pathway. We were able to
validate the presence of a substantial amount of EGFR on
six bladder cancer cell lines. However, further validation
of our findings is needed on independent cohorts.
Methylation is an attractive investigative tool for the
study of aggressive cancer given that methylation is a
reversible process. In myelodysplastic syndrome and
AML, demethylating agents have been shown to have
some effectiveness [43]. In this study, our integrative ap-
proach supports the findings of others showing that
Fig. 5 Flow cytometry analysis demonstrating expression of EGFR on the cell surface of various cell lines. The curve shaded gray represents
binding of rat monoclonal antibody to human EGFR tagged with phycoerythrin (PE). The curve without shading (white) represents binding of an
isotype control, which in the case was a PE-tagged monoclonal rat IgG2a kappa. The vertically written numbers next to each peak represent me-
dian fluorescence intensity for isotype control and anti-EGFR PE. For all cell lines tested (UMUC1, UMUC5, Scaber, HT1376, SW780, and 253 J), there
was substantial EGFR expression compared with isotype control
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hypermethylation of specific genes is associated with ag-
gressive urothelial carcinoma. The findings of this work
may have application in the prevention of new disease
and the reduction of disease recurrence in those with
existing disease.
Conclusions
Taken together, our integrative approach to identify bio-
logically active methylation events has demonstrated
anomalies in methylation in invasive urothelial carcin-
oma. Genes involved in oncologically relevant pathways
including EGFR were found to be hypomethylated. We
found a substantial increase in methylation in pathways
involved in the management of free radicals including
NRF2 and glutathione. It appears that multiple of genes
with tumor suppressor activity may be associated with
overall poor prognosis.
Additional file
Additional file 1: Table S1. (XLSX 58 kb)
Additional file 2: Table S2. Full pathway list. (XLSX 55 kb)
Additional file 3: Table S3. (DOCX 20 kb)
Additional file 4: Table S4. (DOCX 13 kb)
Abbreviations
TCGA: The Cancer Genome Atlas Project
Acknowledgements
None.
Funding
None.
Availability of data and materials
All data are available from the sources listed in the manuscript—TCGA data
portal and cbioportal.com.
Authors’ contributions
TS performed the statistical analysis and the lead author in the manuscript
preparation. MVM is the co-lead author on the study design and assisted in
the manuscript preparation and revisions. PKA input on the design of the study
and assisted in the manuscript preparation and revisions. RR performed the
cell line-based experiments and assisted in the manuscript preparation and
revisions. SPP is the co-lead author on the study design, assisted in the
manuscript preparation and revisions, and the corresponding author.
All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for participation for all patients was obtained through The Cancer
Genome Atlas Project.
Consent for publication
N/A.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Urology, University of California, Mail code 1695, 550 16th
Street, 6th Floor, San Francisco, CA 94143, USA. 2Urologic Oncology Branch,
Center for Cancer Research, National Cancer Institute, Building 10—Hatfield
CRC, Room 2-5952, Bethesda, MD 20892-1210, USA.
Received: 9 January 2017 Accepted: 30 January 2018
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;
65:5–29.
2. Rübben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural
history and treatment of low and high risk superficial bladder tumors. J
Urol. 1988;139:283–5.
3. Ghoneim MA, Abdel-Latif M, El-Mekresh M, Abol-Enein H, Mosbah A,
Ashamallah A, et al. Radical cystectomy for carcinoma of the bladder: 2,720
consecutive cases 5 years later. J Urol. 2008;180:121–7.
4. Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy
for bladder cancer: a contemporary series. J Urol. 2001;165:1111–6.
5. Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Sugano K, et al.
Unique DNA methylation patterns distinguish noninvasive and invasive
urothelial cancers and establish an epigenetic field defect in premalignant tissue.
Cancer Research American Association for Cancer Research. 2010;70:8169–78.
6. Catto JWF, Azzouzi A-R, Rehman I, Feeley KM, Cross SS, Amira N, et al.
Promoter hypermethylation is associated with tumor location, stage, and
subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23:
2903–10.
7. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, et al.
Promoter hypermethylation identifies progression risk in bladder cancer.
Clin Cancer Res. 2007;13:2046–53.
8. Ning B, Li W, Zhao W, Wang R. Targeting epigenetic regulations in cancer.
Acta Biochim Biophys Sin Shanghai. 2016;48:97–109.
9. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, et al.
Comprehensive genome methylation analysis in bladder cancer:
identification and validation of novel methylated genes and application of
these as urinary tumor markers. Clin Cancer Res American Association for
Cancer Research. 2011;17:5582–92.
10. Lauss M, Aine M, Sjödahl G, Veerla S, Patschan O, Gudjonsson S, et al. DNA
methylation analyses of urothelial carcinoma reveal distinct epigenetic
subtypes and an association between gene copy number and methylation
status. Epigenetics. 2012;7:858–67.
11. Wang KS, Liu X. Integrative analysis of genome-wide expression and
methylation data. J Biom Biostat. 2013;
12. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al.
Comprehensive molecular characterization of muscle invasive bladder
cancer. Cell. 2017;171(3):540–56.
13. Cancer Genome Atlas Research Network. Comprehensive molecular
characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22.
14. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA
methylation array with single CpG site resolution. Genomics. 2011;98:288–95.
15. Zhu Y, Qiu P, Ji Y. TCGA-Assembler: open-source software for retrieving and
processing TCGA data. Nat Meth. 2014;11:599–600.
16. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for
differential expression analysis of digital gene expression data.
Bioinformatics. 2009;26:139–40.
17. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers
differential expression analyses for RNA-sequencing and microarray studies.
Nucleic Acids Res. 2015;43:e47.
18. Gevaert O. MethylMix: an R package for identifying DNA methylation-driven
genes. Bioinformatics. 2015;31:1839–41.
19. Gevaert O, Tibshirani R, Plevritis SK. Pancancer analysis of DNA methylation-
driven genes using MethylMix. Genome Biol. 2015;16:17.
20. Kamburov A, Wierling C, Lehrach H, Herwig R. ConsensusPathDB—a
database for integrating human functional interaction networks. Nucleic
Acids Res. 2009;37:D623–8.
21. Welty C, Sanford T, Wright J, Carroll P, Meng M, Porten S. PD41-10 the
impact of tumor stage on cancer specific survival in patients with node
positive urothelial cancer of the bladder. J Urol. 2015;193:e843–4.
22. Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin
North Am. 2015;29:177–89–vii.
Sanford et al. Clinical Epigenetics  (2018) 10:19 Page 9 of 11
23. Black PC, Agarwal PK, CPN D. Targeted therapies in bladder cancer—an update.
Urologic Oncology: Seminars and Original Investigations. 2007;25:433–8.
24. Sharma P, Sharma R, Vijay M, Tiwari P, Goel A, Kundu A. Emphysematous
pyelonephritis: our experience with conservative management in 14 cases.
Urol Ann. 2013;5:157.
25. Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81:
303–11.
26. Kim Y-J, Yoon H-Y, Kim JS, Kang HW, Min B-D, Kim S-K, et al. HOXA9,
ISL1and ALDH1A3methylation patterns as prognostic markers for
nonmuscle invasive bladder cancer: array-based DNA methylation and
expression profiling. Int J Cancer. 2013;133:1135–42.
27. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-
Pursiainen K. Promoter hypermethylation in tumour suppressor genes
shows association with stage, grade and invasiveness of bladder cancer.
Oncology. 2008;75:145–51.
28. Catto JWF, Yates DR, Rehman I, Azzouzi AR, Patterson J, Sibony M, et al.
Behavior of urothelial carcinoma with respect to anatomical location. J Urol.
2007;177:1715–20.
29. Chihara Y, Kanai Y, Fujimoto H, Sugano K, Kawashima K, Liang G, et al.
Diagnostic markers of urothelial cancer based on DNA methylation analysis.
BMC Cancer. 4 ed. 2013;13:275.
30. Kandimalla R, van Tilborg AAG, Kompier LC, Stumpel DJPM, Stam RW,
Bangma CH, et al. Genome-wide analysis of CpG island methylation in
bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific
prognostic markers. Eur Urol. 2012;61:1245–56.
31. Marsit CJ, Houseman EA, Christensen BC, Gagne L, Wrensch MR, Nelson HH,
et al. Identification of methylated genes associated with aggressive bladder
cancer. PLoS One. 2010;5:e12334.
32. Network TCGAR. Comprehensive molecular characterization of urothelial
bladder carcinoma. Nature Nature Publishing Group. 2014;507:315–22.
33. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational
landscape and significance across 12 major cancer types. Nature. 2013;502:
333–9.
34. Fan S, Zhang X. CpG island methylation pattern in different human tissues
and its correlation with gene expression. Biochem Biophys Res Commun.
2009;383:421–5.
35. Dhawan D, Hamdy FC, Rehman I, Patterson J, Cross SS, Feeley KM, et al.
Evidence for the early onset of aberrant promoter methylation in urothelial
carcinoma. J Pathol. 2006;209:336–43.
36. Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B, et al.
Aberrant promoter methylation of multiple genes during pathogenesis of
bladder cancer. Cancer Epidemiol Biomarkers Prev American Association for
Cancer Research. 2008;17:2786–94.
37. Kalinina EV, Chernov NN, Novichkova MD. Role of glutathione, glutathione
transferase, and glutaredoxin in regulation of redox-dependent processes.
Biochemistry Moscow. 2015;79:1562–83.
38. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important
stress response mechanism. Trends Mol Med. 2004;10:549–57.
39. Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, et al. Nrf2 is essential
for the chemopreventive efficacy of oltipraz against urinary bladder
carcinogenesis. Cancer Res. 2004;64:6424–31.
40. Shen SS, Smith CL, Hsieh J-T, Yu J, Kim IY, Jian W, et al. Expression of
estrogen receptors-alpha and -beta in bladder cancer cell lines and human
bladder tumor tissue. Cancer. 2006;106:2610–6.
41. Hoffman KL, Lerner SP, Smith CL. Raloxifene inhibits growth of RT4
urothelial carcinoma cells via estrogen receptor-dependent induction of
apoptosis and inhibition of proliferation. Horm Cancer. 2013;4:24–35.
42. Dellagrammaticas D, Bryden AA, Collins GN. Regression of metastatic
transitional cell carcinoma in response to tamoxifen. J Urol. 2001;165:1631.
43. Issa J-PJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, et al. Safety
and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic
syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-
escalation phase 1 study. Lancet Oncol. 2015;16:1099–110.
44. Menendez L, Walker D, Matyunina LV, Dickerson EB, Bowen NJ, Polavarapu
N, et al. Identification of candidate methylation-responsive genes in ovarian
cancer. Mol Cancer. 2007;6:10.
45. Xu J, Sylvester R, Tighe AP, Chen S, Gudas LJ. Transcriptional activation of
the suppressor of cytokine signaling-3 (SOCS-3) gene via STAT3 is increased
in F9 REX1 (ZFP-42) knockout teratocarcinoma stem cells relative to wild-
type cells. J Mol Biol. 2008;377:28–46.
46. Wei J-H, Haddad A, Wu K-J, Zhao H-W, Kapur P, Zhang Z-L, et al. A CpG-
methylation-based assay to predict survival in clear cell renal cell carcinoma.
Nat Commun. 2015;6:8699.
47. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh J-T, Factor VM, et al. Inactivation
of Ras GTPase-activating proteins promotes unrestrained activity of wild-
type Ras in human liver cancer. J Hepatol. 2011;54:311–9.
48. Yoon H-Y, Kim Y-J, Kim JS, Kim Y-W, Kang HW, Kim WT, et al. RSPH9
methylation pattern as a prognostic indicator in patients with non-muscle
invasive bladder cancer. Oncol. Rep. Spandidos Publications. 2016;35:1195–203.
49. Yamada N, Yasui K, Dohi O, Gen Y, Tomie A, Kitaichi T, et al. Genome-wide
DNA methylation analysis in hepatocellular carcinoma. Oncol Rep. 2016;35:
2228–36.
50. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD,
Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K,
Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS.
Prognostic and predictive value of tumor vascular endothelial growth factor
gene amplification in metastatic breast cancer treated with paclitaxel with
and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res.
2013;19(5):1281-9. https://doi.org/10.1158/1078-0432.CCR-12-3029.
51. Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H, et al. MiR-185 targets the
DNA methyltransferases 1 and regulates global DNA methylation in human
glioma. Mol Cancer BioMed Central. 2011;10:124.
52. Kennedy MW, Chalamalasetty RB, Thomas S, Garriock RJ, Jailwala P,
Yamaguchi TP. Sp5 and Sp8 recruit β-catenin and Tcf1-Lef1 to select
enhancers to activate Wnt target gene transcription. Proc Natl Acad Sci U S
A. 2016;113:3545–50.
53. Misawa K, Mochizuki D, Imai A, Endo S, Mima M, Misawa Y, et al. Prognostic
value of aberrant promoter hypermethylation of tumor-related genes in
early-stage head and neck cancer. Oncotarget. Impact Journals. 2016;7:
26087–98.
54. Tham C, Chew M, Soong R, Lim J, Ang M, Tang C, et al. Postoperative
serum methylation levels of TAC1 and SEPT9 are independent predictors of
recurrence and survival of patients with colorectal cancer. Cancer. 2014;120:
3131–41.
55. Liu Y, Tham CK, Ong SYK, Ho KS, Lim JF, Chew MH, et al. Serum methylation
levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal
cancers: a pilot study. Biomarkers. 2013;18:399–405.
56. Kitchen MO, Bryan RT, Emes RD, Glossop JR, Luscombe C, Cheng KK, et al.
Quantitative genome-wide methylation analysis of high-grade non-muscle
invasive bladder cancer. Epigenetics. 2016;11:237–46.
57. Shui IM, Wong C-J, Zhao S, Kolb S, Ebot EM, Geybels MS, et al. Prostate
tumor DNA methylation is associated with cigarette smoking and adverse
prostate cancer outcomes. Cancer. 2016;122:2168–77.
58. Ushmorov A, Leithäuser F, Ritz O, Barth TFE, Möller P, Wirth T. ABF-1 is
frequently silenced by promoter methylation in follicular lymphoma, diffuse
large B-cell lymphoma and Burkitt’s lymphoma. Leukemia. 2008;22:1942–4.
59. Sugimachi K, Matsumura T, Shimamura T, Hirata H, Uchi R, Ueda M, et al.
Aberrant methylation of FOXE1 contributes to a poor prognosis for patients
with colorectal cancer. Ann Surg Oncol. 2016;
60. Venza I, Visalli M, Tripodo B, De Grazia G, Loddo S, Teti D, et al. FOXE1 is a
target for aberrant methylation in cutaneous squamous cell carcinoma. Br J
Dermatol. 2010;162:1093–7.
61. Park E, Gong E-Y, Romanelli MG, Lee K. Suppression of estrogen receptor-
alpha transactivation by thyroid transcription factor-2 in breast cancer cells.
Biochem Biophys Res Commun. 2012;421:532–7.
62. Landa I, Ruiz-Llorente S, Montero-Conde C, Inglada-Pérez L, Schiavi F,
Leskelä S, et al. The variant rs1867277 in FOXE1 gene confers thyroid cancer
susceptibility through the recruitment of USF1/USF2 transcription factors.
PLoS Genet. 2009;5:e1000637.
63. Yin DT, Xu J, Lei M, Li H, Wang Y, Liu Z, et al. Characterization of the novel
tumor-suppressor gene CCDC67 in papillary thyroid carcinoma. Oncotarget
Impact Journals. 2016;7:5830–41.
64. Park S-J, Jang H-R, Kim M, Kim J-H, Kwon O-H, Park J-L, et al. Epigenetic
alteration of CCDC67 and its tumor suppressor function in gastric cancer.
Carcinogenesis. 2012;33:1494–501.
65. Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, et al.
A prognostic DNA methylation signature for stage I non-small-cell lung
cancer. J Clin Oncol. 2013;31:4140–7.
66. de Groot JS, Pan X, Meeldijk J, van der Wall E, van Diest PJ, Moelans CB.
Validation of DNA promoter hypermethylation biomarkers in breast cancer—a
short report. Cell Oncol (Dordr) Springer Netherlands. 2014;37:297–303.
Sanford et al. Clinical Epigenetics  (2018) 10:19 Page 10 of 11
67. Yuan H, Kajiyama H, Ito S, Yoshikawa N, Hyodo T, Asano E, et al. ALX1
induces snail expression to promote epithelial-to-mesenchymal transition
and invasion of ovarian cancer cells. Cancer Research. American Association
for Cancer Research. 2013;73:1581–90.
68. Kim Y-H, Lee HC, Kim S-Y, Yeom YI, Ryu KJ, Min B-H, et al. Epigenomic analysis
of aberrantly methylated genes in colorectal cancer identifies genes commonly
affected by epigenetic alterations. Ann Surg Oncol. 2011;18:2338–47.
69. Mitchell SM, Ross JP, Drew HR, Ho T, Brown GS, Saunders NFW, et al. A
panel of genes methylated with high frequency in colorectal cancer. BMC
Cancer BioMed Central. 2014;14:54.
70. Ashktorab H, Daremipouran M, Goel A, Varma S, Leavitt R, Sun X, et al. DNA
methylome profiling identifies novel methylated genes in African American
patients with colorectal neoplasia. Epigenetics. 2014;9:503–12.
71. Yu C, Zhang Z, Liao W, Zhao X, Liu L, Wu Y, et al. The tumor-suppressor
gene Nkx2.8 suppresses bladder cancer proliferation through upregulation
of FOXO3a and inhibition of the MEK/ERK signaling pathway.
Carcinogenesis Oxford University Press. 2012;33:678–86.
72. Lin C, Song L, Gong H, Liu A, Lin X, Wu J, et al. Nkx2-8 downregulation
promotes angiogenesis and activates NF-κB in esophageal cancer. Cancer
Research. American Association for Cancer Research. 2013;73:3638–48.
73. Steenbergen RD, Ongenaert M, Snellenberg S, Trooskens G, van der Meide
WF, Pandey D, Bloushtain-Qimron N, Polyak K, Meijer CJ, Snijders PJ, Van
Criekinge W. Methylation-specific digital karyotyping of HPV16E6E7-
expressing human keratinocytes identifies novel methylation events in
cervical carcinogenesis. J Pathol. 2013;231(1):53-62. https://doi.org/10.1002/
path.4210.
74. Molina-Pinelo S, Salinas A, Moreno-Mata N, Ferrer I, Suarez R, Andrés-León E,
et al. Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker
patients with lung cancer. Oncotarget. 2016;
75. Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X,
Alvarez S, et al. A comprehensive microarray-based DNA methylation study
of 367 hematological neoplasms. PLoS One. 2009;4:e6986.
76. Lindqvist BM, Wingren S, Motlagh PB, Nilsson TK. Whole genome DNA
methylation signature of HER2-positive breast cancer. Epigenetics. 2014;9:
1149–62.
77. Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, et al.
Genome-wide screen of promoter methylation identifies novel markers in
melanoma. Genome Res. 2009;19:1462–70.
78. Ma K, Cao B, Guo M. The detective, prognostic, and predictive value of DNA
methylation in human esophageal squamous cell carcinoma. Clin
Epigenetics BioMed Central. 2016;8:43.
79. Cheng Y, Geng H, Cheng SH, Liang P, Bai Y, Li J, et al. KRAB zinc finger
protein ZNF382 is a proapoptotic tumor suppressor that represses multiple
oncogenes and is commonly silenced in multiple carcinomas. Cancer Res.
2010;70:6516–26.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sanford et al. Clinical Epigenetics  (2018) 10:19 Page 11 of 11
